Stiris Research Inc. Announces the First Site Initiated In Phase I Non-Small Cell Lung Cancer Trial
Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces the first site initiated in a Phase I, Non-Small Cell Lung Cancer (NSCLC) study.
“Stiris Research is excited to announce, that on November 8, 2023, that the initiation and activation of our first site in the Phase I NSCLC trial was completed. The study is now open to recruitment and screening of subjects. This important step forward will advance our client’s goal to bring a new treatment to patients with advanced NSCLC.” said Shantal Feltham, President & CEO.
Non-small cell lung cancer (NSCLC) is any type of epithelial lung cancer other than small cell lung cancer (SCLC). NSCLC arises from the epithelial cells of the lung of the central bronchi to terminal alveoli. The histological type of NSCLC correlates with site of origin, reflecting the variation in respiratory tract epithelium of the bronchi to alveoli. Patients with locally advanced unresectable disease may achieve long-term survival with radiation therapy combined with chemotherapy. Patients with advanced metastatic disease may achieve improved survival and palliation of symptoms with chemotherapy, targeted agents, and other supportive measures. (https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq#:~:text=NSCLC%20is%20any%20type%20of,occur%20in%20unusual%20histologic%20variants.)
About Stiris Research
Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.
For more information, please contact: